A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA's Purple Book.

AAPS PharmSciTech

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.

Published: April 2024

AI Article Synopsis

  • Biopharmaceuticals make up about 10% of the drug market, yet they dominated sales in 2023, with eight of the top ten products being biopharmaceuticals.
  • The study analyzed FDA's Purple Book to understand market trends, biologics distribution, and highlighted ongoing challenges such as molecular instability and formulation design despite advancements in biotechnology and faster approval processes.
  • It also examined biological formulations and proposed strategies for administration routes, dosage forms, packaging, and excipients, emphasizing the need for innovative delivery methods to address evolving healthcare challenges.

Article Abstract

Although biopharmaceuticals constitute around 10% of the drug landscape, eight of the ten top-selling products were biopharmaceuticals in 2023. This study did a comprehensive analysis of the FDA's Purple Book database. Firstly, our research uncovered market trends and provided insights into biologics distributions. According to the investigation, although biotechnology has advanced and legislative shifts have made the approval process faster, there are still challenges to overcome, such as molecular instability and formulation design. Moreover, our research comprehensively analyzed biological formulations, pointing out significant strategies regarding administration routes, dosage forms, product packaging, and excipients. In conjunction with biologics, the widespread integration of innovative delivery strategies will be implemented to confront the evolving challenges in healthcare and meet an expanding array of treatment needs.

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12249-024-02802-0DOI Listing

Publication Analysis

Top Keywords

comprehensive analysis
8
fda's purple
8
purple book
8
analysis biopharmaceutical
4
biopharmaceutical products
4
products listed
4
listed fda's
4
book biopharmaceuticals
4
biopharmaceuticals constitute
4
constitute 10%
4

Similar Publications

(L.) Jacq. has anti-inflammatory, analgesic, haemostatic and antioxidant effects, but its pharmacological components are still unclear.

View Article and Find Full Text PDF

Carbohydrate-active enzymes (CAZymes) involved in the degradation of plant cell walls and/or the assimilation of plant carbohydrates for energy uptake are widely distributed in microorganisms. In contrast, they are less frequent in animals, although there are exceptions, including examples of CAZymes acquired by horizontal gene transfer (HGT) from bacteria or fungi in several of phytophagous arthropods and plant-parasitic nematodes. Although the whitefly Bemisia tabaci is a major agricultural pest, knowledge of HGT-acquired CAZymes in this phloem-feeding insect of the Hemiptera order (subfamily Aleyrodinae) is still lacking.

View Article and Find Full Text PDF

The recent U.S. Food and Drug Administration guidance on complex innovative trial designs acknowledges the use of Bayesian strategies to incorporate historical information based on clinical expertise and data similarity.

View Article and Find Full Text PDF

Background: Hallux valgus (HV) is a complex, multiplanar deformity. In this study, we examined the interrelationships between various components of this deformity using weightbearing computed tomography (WBCT). We hypothesized that the severity of traditional axial plane deformities would correlate with malpositioning of the metatarsosesamoid complex, first-ray coronal rotational deformity, and malalignment of the hindfoot and midfoot.

View Article and Find Full Text PDF

Efficacy of Orthognathic Surgery in OSAS Patients: A Systematic Review and Meta-Analysis.

J Oral Rehabil

January 2025

Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India.

Background: Obstructive sleep apnea syndrome (OSAS) is a prevalent condition characterised by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to disrupted sleep and associated morbidities. Orthognathic surgery (OGS) has been proposed as a treatment option for OSAS, aimed at anatomically repositioning the maxillofacial structures to alleviate airway obstruction. This systematic review and meta-analysis aimed to evaluate the efficacy of OGS in reducing apnea-hypopnea index (AHI) and Epworth Sleepiness Scale (ESS) scores among OSAS patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!